Obetat Biopharma

Our vision

OBETAT Biopharma is, a pre-clinical stage company developing an innovative new class of potent and safe anti-obesity peptide based drug meeting unmet needs of suppressing and treating severe obesity, is seeking USA and international strategic partners interested in entering the U.S. and global markets.

Our strategy

Develop our leading compound TatdMt, a first-in-class rapid acting fat mass reducing drug, targeted for severe obesity.

We are exploring investment opportunities to complete IND enabling works, reach important development and regulatory milestones in collaboration with venture capital, pharmaceutical and biotechnology companies to develop and market products based on its core technology platform and its application to a variety of therapeutic indications.